Finally, we found that low concentration of anlotinib could decrease the expression of PD‐L1 only in VECs via inhibiting the PI3K/AKT pathway; however, the same effect was not observed in cancer cells (Supplementary Figure S8). The gene discussed is AKT1; the disease is cancer.